InvestorsHub Logo
Followers 14
Posts 306
Boards Moderated 0
Alias Born 01/17/2021

Re: rosemountbomber post# 371079

Friday, 02/18/2022 1:00:04 PM

Friday, February 18, 2022 1:00:04 PM

Post# of 425918
Suitable comparator data from Amarin


evaluation

The Institute for Quality and Efficiency in Health Care (IQWiG) last checked in 2022 whether icosapent-ethyl has advantages or disadvantages for people with a high cardiovascular risk compared to standard therapies.

However, the manufacturer did not provide any suitable data to answer this question.

https://www.gesundheitsinformation.de/icosapent-ethyl-vazkepa-bei-hohem-herz-kreislauf-risiko.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News